Cargando…

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients

BACKGROUND: Integrin β3 is involved in tumor and endothelial cell biology as well as in platelet aggregation. Herein, we evaluated the predictive potential of three germline single nucleotide polymorphisms (SNPs) in the integrin β3 gene (rs3809865, rs5918 and rs4642) to predict the risk of venous th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bianconi, Daniela, Schuler, Alexandra, Pausz, Clemens, Geroldinger, Angelika, Kaider, Alexandra, Lenz, Heinz-Josef, Kornek, Gabriela, Scheithauer, Werner, Zielinski, Christoph C., Pabinger, Ingrid, Ay, Cihan, Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496222/ https://www.ncbi.nlm.nih.gov/pubmed/26440977 http://dx.doi.org/10.1016/j.thromres.2015.08.010

Ejemplares similares

Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
por: Ay, Cihan, et al.
Publicado: (2020)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

ABO blood group type and risk of venous thromboembolism in patients with cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study
por: Obermeier, Hanna L., et al.
Publicado: (2019)

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality
por: Riedl, Julia, et al.
Publicado: (2014)

Plasma Clot Properties in Patients with Pancreatic Cancer
por: Thaler, Johannes, et al.
Publicado: (2023)

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
por: Moik, Florian, et al.
Publicado: (2020)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2020)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2018)

Prevention of venous thromboembolism in ambulatory patients with cancer
por: Khorana, Alok A, et al.
Publicado: (2020)

Integrins in the Spotlight of Cancer
por: Bianconi, Daniela, et al.
Publicado: (2016)

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
por: Kieler, Markus, et al.
Publicado: (2020)

Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2019)

Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence
por: Nopp, Stephan, et al.
Publicado: (2022)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

How I treat cancer-associated thrombosis
por: Moik, Florian, et al.
Publicado: (2020)

Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options
por: Ay, Cihan, et al.
Publicado: (2017)

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
por: Prager, Gerald W, et al.
Publicado: (2014)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
por: Muñoz, Andrés, et al.
Publicado: (2023)

Fibrinolysis and bleeding of unknown cause
por: Mehic, Dino, et al.
Publicado: (2021)

Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
por: Ay, Cihan, et al.
Publicado: (2021)

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
por: Farge, Dominique, et al.
Publicado: (2022)

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
por: Königsbrügge, Oliver, et al.
Publicado: (2017)

Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer
por: Moik, Florian, et al.
Publicado: (2020)

The High Expression of Adhering and Circulating Integrin Serves as a Diagnostic Marker in Venous Thromboembolism
por: Yang, Fan, et al.
Publicado: (2022)

A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank
por: Mehic, Dino, et al.
Publicado: (2023)

Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need
por: Brenner, Benjamin, et al.
Publicado: (2022)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

Pain management in hemophilia: expert recommendations
por: Stromer, Waltraud, et al.
Publicado: (2021)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
por: Mir Seyed Nazari, P., et al.
Publicado: (2018)

Venous thromboembolism /
por: Hirsh, Jack, 1935-
Publicado: (1981)

Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry
por: Bikdeli, Behnood, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v6gc3psog5sq80o09sharlhmgq